Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
Abstract Background The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespecified subgroup analyses evaluated efficacy by country in the FOCUS stu...
Main Authors: | Egilius L. H. Spierings, Mikko Kärppä, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Uwe Reuter |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | https://doi.org/10.1186/s10194-021-01232-8 |
Similar Items
-
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-03-01) -
Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials
by: Stephen D. Silberstein, et al.
Published: (2021-01-01) -
Fremanezumab in the treatment of migraines: evidence to date
by: Robblee J, et al.
Published: (2019-08-01) -
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
by: Stephen D. Silberstein, et al.
Published: (2020-09-01) -
Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries
by: Lena Ohlsson, et al.
Published: (2018-08-01)